Amber Pharmacy to dispense Celgene's Inrebic

Press enter to search
Close search
Open Menu

Amber Pharmacy to dispense Celgene's Inrebic

By Sandra Levy - 09/05/2019
Amber Pharmacy, a subsidiary of Hy-Vee has been selected to be a specialty pharmacy network partner for Celgene’s new product Inrebic (fedratinib).

The Food and Drug Administration approved Inrebic on Aug. 16, 2019, for the treatment of adult patients with certain types of myelofibrosis, or MF.

MF is a type of blood cancer in which the bone marrow is replaced by fibrous scar tissue. Excessive scar tissue can disrupt the body’s production of normal red blood cells which can lead to anemia, weakness and fatigue. It can also lower the number of blood-clotting cells called platelets, which increases the risk of bleeding. Other symptoms may include swelling of the spleen and liver.

MF is classified as a myeloproliferative neoplasm. In the absence of treatment, as many as 12% of MF patients will progress and develop acute myeloid leukemia.

“We believe that Inrebic will play an important role in the treatment of patients with MF and we are honored to be selected as a specialty pharmacy provider for this medication,” said Aaron Wiese, Amber Pharmacy president and CEO. “Our high-touch patient support services and oncology clinical expertise offer best-in-class program practices that address all aspects of the health and well-being of our MF patients, and their healthcare team.”

Related Topics